Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(2.71)
# 2,792
Out of 4,456 analysts
206
Total ratings
45.4%
Success rate
1.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Reiterated: Buy | $9 | $3.49 | +157.88% | 19 | Jun 12, 2026 | |
| NRSN NeuroSense Therapeutics | Maintained: Buy | $3 | $0.7574 | +296.09% | 6 | Jun 10, 2026 | |
| COYA Coya Therapeutics | Initiated Coverage: Buy | $12 | $5.50 | +118.18% | 1 | Jun 5, 2026 | |
| CING Cingulate | Maintained: Buy | $10 | $4.96 | +101.61% | 24 | Jun 4, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $10 | $7.74 | +29.20% | 21 | Jun 3, 2026 | |
| PYPD PolyPid | Reiterated: Buy | $9 | $4.75 | +89.47% | 18 | Jun 2, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $38 | $26.44 | +43.72% | 16 | May 29, 2026 | |
| GANX Gain Therapeutics | Reiterated: Buy | $8 | $1.75 | +357.14% | 27 | May 27, 2026 | |
| LBRX LB Pharmaceuticals | Rated: Buy | $31 → $37 | $31.92 | +15.91% | 5 | May 18, 2026 | |
| LGVN Longeveron | Reiterated: Buy | $2 → $3 | $0.7155 | +319.29% | 16 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $26 → $19 | $15.30 | +24.18% | 5 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 → $7 | $2.55 | +174.51% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $1 | $0.67079 | +49.08% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.96 | n/a | 5 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.3009 | n/a | 3 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.9508 | n/a | 2 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $14.48 | n/a | 11 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $55.11 | n/a | 9 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $25.36 | n/a | 6 | Oct 24, 2023 |
CervoMed
Jun 12, 2026
Reiterated: Buy
Price Target: $9
Current: $3.49
Upside: +157.88%
NeuroSense Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: $3
Current: $0.7574
Upside: +296.09%
Coya Therapeutics
Jun 5, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $5.50
Upside: +118.18%
Cingulate
Jun 4, 2026
Maintained: Buy
Price Target: $10
Current: $4.96
Upside: +101.61%
Entrada Therapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $10
Current: $7.74
Upside: +29.20%
PolyPid
Jun 2, 2026
Reiterated: Buy
Price Target: $9
Current: $4.75
Upside: +89.47%
Capricor Therapeutics
May 29, 2026
Reiterated: Buy
Price Target: $38
Current: $26.44
Upside: +43.72%
Gain Therapeutics
May 27, 2026
Reiterated: Buy
Price Target: $8
Current: $1.75
Upside: +357.14%
LB Pharmaceuticals
May 18, 2026
Rated: Buy
Price Target: $31 → $37
Current: $31.92
Upside: +15.91%
Longeveron
May 15, 2026
Reiterated: Buy
Price Target: $2 → $3
Current: $0.7155
Upside: +319.29%
May 14, 2026
Rated: Buy
Price Target: $26 → $19
Current: $15.30
Upside: +24.18%
May 14, 2026
Rated: Buy
Price Target: $5 → $7
Current: $2.55
Upside: +174.51%
Apr 1, 2026
Rated: Buy
Price Target: $30 → $1
Current: $0.67079
Upside: +49.08%
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $2.96
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.3009
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.9508
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $14.48
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $55.11
Upside: n/a
Oct 24, 2023
Maintained: Hold
Price Target: n/a
Current: $25.36
Upside: n/a